scispace - formally typeset
B

Bo Lu

Researcher at Ohio State University

Publications -  390
Citations -  24905

Bo Lu is an academic researcher from Ohio State University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 58, co-authored 353 publications receiving 21823 citations. Previous affiliations of Bo Lu include Wuhan University of Technology & Wuhan University.

Papers
More filters
Journal ArticleDOI

Identification of ICAT as an APC Inhibitor, Revealing Wnt-Dependent Inhibition of APC-Axin Interaction

TL;DR: This study identifies ICAT, a polypeptide previously known to block β-catenin-TCF interaction, as a natural inhibitor of APC and demonstrates that Wnt quickly inhibits the direct interaction betweenAPC and Axin.
Journal ArticleDOI

Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium.

TL;DR: The data suggest that the combination therapy was more effective in destroying tumor vasculature than either treatment alone, and augments tumor-suppressive effects of radiotherapy in Lewis lung carcinoma and GL261 xenographs, possibly through reducing the survival of tumor endothelium.
Journal ArticleDOI

Regional impact of climate on Japanese encephalitis in areas located near the three gorges dam.

TL;DR: The spatial and temporal trends of Japanese encephalitis incidence that occurred in the City of Chongqing were associated with temperature and rainfall, and seasonal fluctuations of climatic variables during this period were observed.
Journal ArticleDOI

Tobacco-Free Pharmacy Laws and Trends in Tobacco Retailer Density in California and Massachusetts

TL;DR: T tobacco-free pharmacy laws are associated with a greater reduction in tobacco retailer density over time in California and Massachusetts, the only 2 US states in which such municipal laws exist.
Journal ArticleDOI

Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.

TL;DR: It is indicated that simultaneous inhibition of EGFR and PI3K could further sensitize the cancer cells to irradiation compared to the single inhibitor with irradiation in vitro and in vivo.